Home Entrepreneur Top stocks to watch this week? 4 biotech stocks you need...

Top stocks to watch this week? 4 biotech stocks you need to know

April 20, 2021

6 minutes of reading

This story originally appeared on Stock market

Should investors follow these top biotech stocks right now?

It has been more than a year since the coronavirus pandemic surprised the world. The result is, Biotechnology stocks Getting more attention than ever before stock market right now. This will be the case when news channels around the globe have and continue to report on coronavirus vaccine development. By expanding, the public, including investors, continues to learn more about the core management processes in the biotechnology industry. If that’s not enough, biotechnology is also a combination of health care and technology industries. On the one hand, its origins in the medical field make it viable as companies work to improve our overall quality of life. On the other hand, with competitive dynamics for technological innovation, there is no shortage of news for investors.

With today’s overall focus on healthcare, I can understand whether investors are optimistic on biotech stocks. We can consider names like Humanigen (NASDAQ: HGEN) For example. The company boasts several end-stage clinical drugs in its cancer product portfolio. Notably, Humanigen’s COVID-19 therapy, Lenzilumab continues to attract investors’ attention. Currently, HGEN shares have increased by more than 170% in the past year. Elsewhere, new players in the biotechnology sector continue to emerge. Last Friday, Recursive Pharmaceuticals (NASDAQ: RXRXAkoya Biological Sciences (NASDAQ: AKYA) and Biomea Fusion (NASDAQ: BMEA) start trading on Nasdaq. With all of these activities in the field of biotechnology, should you consider these Top biotechnology stocks on the stock market today?

Best biotech stocks to watch for April

Moderna Inc.

Moderna is an industry leading mRNA technology based biotechnology company. This platform is used to accelerate drug detection and early development. The company also boasts a rapidly expanding pipeline and a world class team. In addition to creating a vaccine for coronavirus, the company is also researching the prospect of using personalized cancer vaccines based on mRNA and other rare diseases. MRNA shares are currently trading at $ 156.80 at 3:31 p.m. ET and have risen 200 percent last year.

Source: TD Ameritrade TOS

Last week, the company offered a clinical update and offer on its coronavirus vaccine program. First, there were new results from preclinical studies of company-specific vaccine candidate variants that showed increased neutralization titer against coronavirus variants. Second, the company reports that it supplies about 132 million doses of the vaccine globally.

The Moderna team continues to make significant progress with our COVID-19 Vaccine. We look forward to obtaining clinical data from our specific variant-specific booster candidates, as well as clinical data from our Phase 2/3 study of COVID-19 Vaccine in Teenager, “ Stéphane Bancel, CEO of Moderna said. With all of this in mind, would you consider adding MRNA stock to your watchlist?

[Read More] Square (SQ) Vs Futu Holdings (FUTU): Which Fintech stock should I buy?

Pfizer Inc.

Pfizer is a research-based global biopharmaceutical company. It is involved in the development and production of health care products. The company also boasts a global portfolio of drugs and vaccines. With 25,000 clinical researchers, the company focuses on pharmaceutical development and innovation. PFE shares are currently trading at $ 39.06 at 3:31 p.m. ET. Late last month, the company announced positive top-notch results in a Phase 3 adolescent trial to study the coronavirus vaccine.

best biotechnology stocks (PFE stocks)
Source: TD Ameritrade TOS

Specifically, the company reported that the adolescent vaccine from 12 to 15 years of age demonstrated 100% efficacy and a strong antibody response. For reference, this figure exceeds previously reported among vaccinated participants aged 16 to 25 years. The company is urgently looking to expand vaccine licensing for younger people and will submit proposed amendments to the Emergency Use License in the coming weeks and to other regulators. In the world.

With no vaccines available for school children yet, can Pfizer reach another milestone? With that in mind, is PFE stock worth adding to your portfolio?

[Read More] Top technology stocks to buy now? 3 Earnings Report This Week

Johnson & Johnson

Johnson & Johnson (JNJ) is a multinational corporation that develops medical devices and pharmaceuticals. With over 130 years of experience, it is the world’s largest healthcare company. Impressively, the company is comprised of about 250 subsidiaries operating in 60 countries. Its products are sold in over 175 countries. JNJ shares are currently trading at $ 166.24 at 3:32 p.m. ET and jumped 2.32 percent on Tuesday’s opening bell. Investors appear to be reacting to the company’s latest earnings report today.

best biotechnology stocks (shares JNJ)
Source: TD Ameritrade TOS

In particular, the company posted first quarter revenue of $ 22.3 billion, up 7.9% year-on-year. The company also reported earnings per share of $ 2.32, up 6.9% from a year earlier. The company also announced that their dividends increased 5% to $ 1.06 per share. This sizable first quarter performance was driven by momentum in the company’s core medical and pharmaceutical businesses. To achieve this goal, JNJ not only provides financing but also continues to develop its robust product system. If so, all of this is testament to the company’s strength and resilience during this pandemic. Would you add JNJ stock to your watchlist for these reasons?

[Read More] Best stocks to buy now? 4 online gambling stocks for your listing

Crispr therapy

Another top biotech stock in focus right now is Crispr Therapeutics. For some contexts, the Swiss-American biotechnology company is a leading name in the gene editing technology industry. For the most part, it is currently developing genetically modified drugs using its proprietary CRISPR / Cas9 platform. Through this background, Crispr mainly focuses on the treatment of rare diseases and cancers.

biotechnology stocks to buy now (CRSP shares)
Source: TD Ameritrade TOS

Given the wide range of possible applications of the technology, investors may be looking at CRSP stock right now. This seems true as the CRSP stock has more than doubled in value over the past year. In fact, the company’s stock is making headlines today thanks to its latest announcement.

Specifically, Crispr announced an amendment to its current partnership with Vertex Pharmaceuticals (NASDAQ: VRTX). Together with the biotechnology giant, Crispr is working to develop, manufacture and commercialize CTX001, a gene-based treatment for sickle cell disease. More importantly, the modifications will see Crispr getting $ 900 million in upfront payments and $ 200 million in critical payouts. On top of that, Crispr will receive 40% of the potential future profits from the sale of the treatment. Although Vertex is likely to lead the way in this project, Crispr biotechnology is nonetheless a key component. Could this make CRSP stock worth watching now?



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments